Atopic Dermatitis

Continuing their discussion about safety, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, take a closer look at conjunctivitis data from the long-term use of dupilumab

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the design of the LIBERTY-AD open-label extension trial and share clinical context regarding safety findings.

Thought leaders share strategies for talking to patients about the importance of treatment adherence in the long-term management of atopic dermatitis.

Recommendations were made for patients to help relieve inflammation, itching and infections.

JAK inhibitors may cause less adverse events compared with traditional systemic therapies.

In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, evaluate the effect of the rapidly changing therapeutic landscape in atopic dermatitis.

Results from the test reveal that high levels of the immune biomarker Thymus and Activation-Regulated Chemokine (TARC) in babies increases their chances of developing atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the burden of atopic dermatitis and discuss how they talk to patients about the impact their disease has on their lives.

In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In this DermView series recap, Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the changing landscape of atopic dermatitis treatment options and what is on the horizon.

In part 1 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Patients are finding relief in alternative therapy for the chronic skin disease.

Catch up on coverage from the 2022 Revolutionizing Atopic Dermatitis Conference.

Drs Raj Chovatiya and Neal Bhatia summarize their final thoughts on the available treatment options for the management of atopic dermatitis.

Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.

Experts in dermatology discuss the use of oral and topical JAK inhibitors in clinical practice and their reflection of overarching treatment guidelines and indications.

At the RAD 2022 Conference, Keri Kelley, Senior Outreach and Community Manager at Global Parents for Eczema Research discussed a program aimed at providing support for eczema caregivers.

Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.

Raj Chovatiya, MD, PhD, and Neal Bhatia, MD, share their thoughts on the clinical implications of the rapid expansion of the atopic dermatitis treatment armamentarium.

At the RAD 2022 Conference, Steve Xu, MD, MSc, explains how a wearable sensor can better track the progression of atopic dermatitis while a patient is sleeping.

Jonathan Silverberg, MD, PhD, MPHS, gives an overview of topical therapies for atopic dermatitis at the 2022 virtual RAD conference.

At the 2022 RAD virtual conference, a dermatologist examines treatment options for AD in various racial and ethnic groups.

A 2022 RAD Conference abstract presentation showed the epidemiology of type 2 associated conditions included in patients with AD.

At the 2022 RAD Conference, a Harvard University psychologist discusses ways that practitioners can help identify and treat children with adverse mental health outcomes as a result of atopic dermatitis.

A 2022 RAD Conference poster presentation explores the efficacy of the therapy for the treatment or prevention of AD.

A 2022 RAD Conference poster presentation explored how to better support caregivers of children with atopic dermatitis.

A poster presentation from the 2022 RAD Conference analyzed manifestations of atopic dermatitis across racial groups.